Estudo sobre discriminação condicional em ratos Wistar com uso de estimulação de dimensão olfativa: uma replicação parcial de Iversen (2008)

A Análise do Comportamento apresenta o empirismo como uma de suas principais características. Uma boa parte dos conhecimentos criados pela Análise do Comportamento baseia-se em experimentos feitos com sujeitos infra-humanos, sendo a maior parte destes experimentos conduzidos com ratos ou pombos como sujeitos experimentais. Encontrar estímulos que podem se tornar discriminativos para comportamentos dos sujeitos é, portanto, de grande importância para que se possam conduzir experimentos. Talvez por uma razão prática a maior parte dos experimentos utiliza estimulação de dimensão visual ou sonora em ratos. Iversen (2008) apresenta um experimento no qual o comportamento de sujeitos infra-humanos (ratos) é colocado sob controle condicional, e no procedimento o controle condicional foi estabelecido utilizando-se estimulação de tipo olfativa ou tátil. Como a experimentação com sujeitos infra-humanos é de grande relevância para a Análise do Comportamento, faz-se necessária a investigação de outros estímulos que podem se tornar discriminativos para o comportamento dos sujeitos experimentais. O presente estudo replicou parte do procedimento de Iversen (2008), com o objetivo de analisar a possibilidade de se utilizar a estimulação olfativa como estímulo para experimentos de discriminação condicional em ratos da raça Wista

Fluphenazine decanoate (depot) and enanthate for schizophrenia

Background: Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance. The benefits gained by long-acting preparations, however, may be offset by a higher incidence of adverse effects. Objectives: To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes. Search methods: We searched the Cochrane Schizophrenia Group's Trials Register (February 2011 and October 16, 2013), which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. Selection criteria: We considered all relevant randomised controlled trials (RCTs) focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations. Data collection and analysis: We reliably selected, assessed the quality, and extracted data of the included studies. For dichotomous data, we estimated risk ratio (RR) with 95% confidence intervals (CI). Analysis was by intention-to-treat. We used the mean difference (MD) for normal continuous data. We excluded continuous data if loss to follow-up was greater than 50%. Tests of heterogeneity and for publication bias were undertaken. We used a fixed-effect model for all analyses unless there was high heterogeneity. For this update. we assessed risk of bias of included studies and used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to create a 'Summary of findings' table. Main results: This review now includes 73 randomised studies, with 4870 participants. Overall, the quality of the evidence is low to very low.Compared with placebo, use of fluphenazine decanoate does not result in any significant differences in death, nor does it reduce relapse over six months to one year, but one longer-term study found that relapse was significantly reduced in the fluphenazine arm (n = 54, 1 RCT, RR 0.35, CI 0.19 to 0.64, very low quality evidence). A very similar number of people left the medium-term studies (six months to one year) early in the fluphenazine decanoate (24%) and placebo (19%) groups, however, a two-year study significantly favoured fluphenazine decanoate (n = 54, 1 RCT, RR 0.47, CI 0.23 to 0.96, very low quality evidence). No significant differences were found in mental state measured on the Brief Psychiatric Rating Scale (BPRS) or in extrapyramidal adverse effects, although these outcomes were only reported in one small study each. No study comparing fluphenazine decanoate with placebo reported clinically significant changes in global state or hospital admissions.Fluphenazine decanoate does not reduce relapse more than oral neuroleptics in the medium term (n = 419, 6 RCTs, RR 1.46 CI 0.75 to 2.83, very low quality evidence). A small study found no difference in clinically significant changes in global state. No difference in the number of participants leaving the study early was found between fluphenazine decanoate (17%) and oral neuroleptics (18%), and no significant differences were found in mental state measured on the BPRS. Extrapyramidal adverse effects were significantly less for people receiving fluphenazine decanoate compared with oral neuroleptics (n = 259, 3 RCTs, RR 0.47 CI 0.24 to 0.91, very low quality evidence). No study comparing fluphenazine decanoate with oral neuroleptics reported death or hospital admissions.No significant difference in relapse rates in the medium term between fluphenazine decanoate and fluphenazine enanthate was found (n = 49, 1 RCT, RR 2.43, CI 0.71 to 8.32, very low quality evidence), immediate- and short-term studies were also equivocal. One small study reported the number of participants leaving the study early (29% versus 12%) and mental state measured on the BPRS and found no significant difference for either outcome. No significant difference was found in extrapyramidal adverse effects between fluphenazine decanoate and fluphenazine enanthate. No study comparing fluphenazine decanoate with fluphenazine enanthate reported death, clinically significant changes in global state or hospital admissions. Authors' conclusions: There are more data for fluphenazine decanoate than for the enanthate ester. Both are effective antipsychotic preparations. Fluphenazine decanoate produced fewer movement disorder effects than other oral antipsychotics but data were of low quality, and overall, adverse effect data were equivocal. In the context of trials, there is little advantage of these depots over oral medications in terms of compliance but this is unlikely to be applicable to everyday clinical practice.Full Tex

Osteopontin: A Novel Regulator at the Cross Roads of Inflammation, Obesity and Diabetes

Since its first description more than 20 years ago osteopontin has emerged as an active player in many physiological and pathological processes, including biomineralization, tissue remodeling and inflammation. As an extracellular matrix protein and proinflammatory cytokine osteopontin is thought to facilitate the recruitment of monocytes/macrophages and to mediate cytokine secretion in leukocytes. Modulation of immune cell response by osteopontin has been associated with various inflammatory diseases and may play a pivotal role in the development of adipose tissue inflammation and insulin resistance. Here we summarize recent findings on the role of osteopontin in metabolic disorders, particularly focusing on diabetes and obesity

Manufacturing and evaluation of low cost apparatus for non-human research in experimental analysis of behavior.

Equipamentos utilizados em pesquisas em Análise Experimental do Comportamento com sujeitos não humanos tiveram uma trajetória intrincada ao próprio estudo do comportamento. Um tipo de equipamento importante nessas pesquisas é a câmara de condicionamento operante. Diversos incrementos foram feitos nessas câmaras, com estes focados no aumento do controle de variáveis independentes e no registro mais preciso de variáveis dependentes. Uma característica de equipamentos atualmente disponíveis no mercado é o seu alto custo de aquisição e a necessidade do uso de software fechado utilizado pelos mesmos. Diante disso, apresenta-se a construção e avaliação de equipamentos não comerciais de baixo custo para pesquisas operantes. Foram construídas duas câmaras de condicionamento, uma para pombos e outra para ratos. Com o objetivo de avaliar o equipamento construído, submeteram-se dois pombos e dois ratos a esquemas de reforço de razão fixa (FR) e razão variável (VR), e dois pombos e dois ratos a esquemas de reforço de intervalo fixo (FI) e intervalo variável (VI). Replicou-se a maior parte dos aspectos da literatura de esquemas de reforço simples com o equipamento apresentado, o que indica sua adequação ao uso em pesquisas de condicionamento operante como uma alternativa viável de baixo custoApparatuses used non-human research in experimental analysis of behavior have had a parallel trajectory to the study of behavior itself. A type of apparatus used in behavioral studies is the operant conditioning chamber. Several improvements have been done to these chambers, focusing in the control of independent variables and more precise registry of dependent variables. A feature of apparatuses available in the market is their high acquisition costs and the need of usage of closed software. In light of this, it is shown the construction and evaluation of alternative low cost apparatuses for behavioral research. Two operant conditioning chambers were built, one for usage with pigeons and the other for the usage with rats. In order to evaluate the apparatus, two pigeons and two rats were submitted to fixed ratio (FR) and variable ratio (VR) schedules of reinforcement, while another two pigeons and two rats were submitted to fixed interval (FI) and variable interval (VI) schedules of reinforcement. The majority of features related to the responding under simple schedules of reinforcement were replicated using the presented apparatus, which indicates its adequacy for the usage in behavioral research as a low cost alternativ

Cosmetics-triggered percutaneous remote control of transgene expression in mice

Synthetic biology has significantly advanced the rational design of trigger-inducible gene switches that program cellular behavior in a reliable and predictable manner. Capitalizing on genetic componentry, including the repressor PmeR and its cognate operator O(PmeR), that has evolved in Pseudomonas syringae pathovar tomato DC3000 to sense and resist plant-defence metabolites of the paraben class, we have designed a set of inducible and repressible mammalian transcription-control devices that could dose-dependently fine-tune transgene expression in mammalian cells and mice in response to paraben derivatives. With an over 60-years track record as licensed preservatives in the cosmetics industry, paraben derivatives have become a commonplace ingredient of most skin-care products including shower gels, cleansing toners and hand creams. As parabens can rapidly reach the bloodstream of mice following topical application, we used this feature to percutaneously program transgene expression of subcutaneous designer cell implants using off-the-shelf commercial paraben-containing skin-care cosmetics. The combination of non-invasive, transdermal and orthogonal trigger-inducible remote control of transgene expression may provide novel opportunities for dynamic interventions in future gene and cell-based therapies